Testing AXT-1003 for advanced blood cancers and solid tumors
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug (AXT-1003) for people with advanced blood cancers (like non-Hodgkin lymphoma) or solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of blood cancer called non-Hodgkin lymphoma (NHL) that has come back or not responded to treatment, OR you have an advanced solid tumor that has spread or cannot be removed by surgery.
- You are generally well enough to be up and doing light activity (ECOG score 0 or 1).
- Your doctor expects you to live at least 3 more months.
- If you are in the expansion part of the study, you must have a tumor that can be measured on a scan.
- Your major organs (like liver, kidneys, and bone marrow) are working well enough.
- If you could become pregnant, you must use effective birth control during the study and for 3 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests kanitinib (CX1003), a new cancer medicine, in people with advanced solid tumors that have come back or stopped responding to standard treatment. The goal is to find a safe dose and see early signs of tumor response.
This trial tests a new drug called ABL103 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective.
This Phase 1/2 trial tests XTX301, a study treatment, in people with advanced solid tumors (cancers) that have already been treated and are not controlled by standard options. It may help if your cancer matches one of the study groups and you meet safety and test-tissue requirements.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This trial tests a new oral drug called SIGX1094R for people with advanced solid tumors that have not responded to other treatments. The study will check if the drug is safe and how well it works, and it requires a tumor tissue sample to look for a specific marker.
This trial tests an experimental drug called IBD0333 for people with advanced solid tumors or lymphoma who have run out of standard options. The drug targets a protein called 4-1BB to help your immune system fight cancer.
Hear when a new Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.